Targeting Cancer STEM cells – finally

Dr.  Weeks’ Comment:  Here is big new.  But I don’t expect you or your oncologist to understand it. It deals with targeting cancer STEM cells. What are cancer STEM cells?  We I have lectured doctors and warned patients about these “tumor initiator” cells for over 7 years  (see these links  this this  ,  this , this  , thisthis and this) but those oncologists offering simply the standard of care could care less about raising the standard and going after the real lethal case of cancer: the stem cell.  But now that money can be made targeting the cancer STEM cell,  you can expect to hear more about these drugs. Of course, Corrective Cancer Care has addressed the cancer STEM cells successfully for over 5 years. (Search “cancer stem cell” at for more information)


OncoMed Pharmaceuticals to Present Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (anti-CSC) Therapeutics

in Five Posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013

REDWOOD CITY, Calif., Oct 14, 2013 (GLOBE NEWSWIRE via COMTEX) — Updated Phase 1b Data for Demcizumab in Non-Small Cell Lung and Pancreatic Cancers

First Public Presentation of Clinical Data From Ongoing Phase 1 Trials for Anti-Notch1 and Fzd8-Fc Programs

OncoMed Pharmaceuticals, Inc. OMED +1.86% , a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported five abstracts had been accepted as poster presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 19-23, 2013 at the Hynes Convention Center in Boston, MA.

These five posters contain results from four of OncoMed’s five clinical stage product development candidates. Two of the five posters represent the first public presentations of clinical data from two novel anti-CSC agents: anti-Notch1 (OMP-52M51), an antibody targeting the Notch1 receptor and inhibiting signaling through this important target in the Notch CSC pathway, and Fzd8-Fc (OMP-54F28), a fusion protein binding Wnt ligands and inhibiting the key Wnt CSC pathway.

Leave a Comment

Your email address will not be published. Required fields are marked *